论文部分内容阅读
目的:分析胸腺肽α1联合恩替卡韦治疗对于乙肝肝硬化患者的乙型肝炎e抗原(HBe Ag)的影响。方法:选取2013年4月至2016年4月于哈尔滨医科大学附属第二医院感染二科住院和门诊复查的患者50例,随机将患者分为两组,应用胸腺肽α1联合恩替卡韦治疗的患者为实验组,共25例,单一应用恩替卡韦治疗的患者为对照组,共25例。比较两组患者治疗前和治疗半年后的肝功能、乙肝病毒载量以及HBe Ag定量。结果:治疗半年后,实验组患者的肝功能和乙肝病毒载量与对照组比较无明显差异(P>0.05),实验组的HBe Ag量明显低于对照组(P<0.05)。结论:胸腺肽α1联合恩替卡韦可以有效的降低HBe Ag量,促进e抗原转阴,减少病毒复制。
Objective: To analyze the effect of thymosin α1 combined with entecavir treatment on hepatitis B e antigen (HBe Ag) in patients with hepatitis B cirrhosis. Methods: From April 2013 to April 2016, 50 patients with inpatient and outpatient infection in the second hospital affiliated to Harbin Medical University were selected and randomly divided into two groups. The patients treated with thymosin α1 and entecavir were included in the experiment Group, a total of 25 cases, a single application of entecavir treatment for the control group, a total of 25 cases. The liver function, hepatitis B virus load and HBeAg quantitation before treatment and six months after treatment were compared between the two groups. Results: After six months’ treatment, there was no significant difference in liver function and hepatitis B virus load between the experimental group and the control group (P> 0.05). The amount of HBe Ag in the experimental group was significantly lower than that of the control group (P <0.05). Conclusion: Thymosin α1 combined with entecavir can effectively reduce the amount of HBeAg, promote anti-e antigen negative, reduce viral replication.